|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
The rs3803185 variant was not significantly associated with CRC risk in an external cohort (MCC-Spain), but it still showed some borderline significance in the pooled analysis of both cohorts (OR = 1.08, 95% CI = 0.98-1.18, P-value = 0.09, log-additive 0, 1, 2 alleles).
|
21819567 |
2011 |
|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Our results suggest that Trp149Stop is not a predisposition allele in breast, prostate, or colorectal cancer in the Finnish population, and, while the Gly65Val variant may increase familial prostate cancer risk and the Cys148Arg change may affect both breast and prostate cancer risk, the evidence is not strong in these data.
|
18337727 |
2008 |
|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Whereas P131L and W149X did not seem to affect CRC risk, C148R did show, for the first time in CRC, statistically significant differences between cases and controls [odds ratio (OR) = 1.45, 95% confidence interval (95% CI) = 1.13-1.86, P = 0.003], sporadic cases and controls (OR = 1.59, 95% CI = 1.13-2.23, P = 0.007) and familial cases and controls (OR = 1.55, 95% CI = 1.10-2.19, P = 0.01) in agreement with a hypothetical moderate increase of the cancer risk linked to the C148R ARLTS1 variant, both in sporadic and familial CRC cases.
|
17449901 |
2007 |
|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
As the first to evaluate the association between Cys148Arg and Trp149Stop and colorectal cancer (CRC) risk, we genotyped 611 cases with CRC (including 77 cases with a first-degree family history) and 539 controls recruited from the German DACHS study.
|
16488076 |
2006 |
|
Malignant Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
The stratification indicated that the Cys148Arg variant is significantly associated with sporadic cancer (CC vs. TT: OR = 1.36, 95% CI = 1.18-1.55) and familial cancer (CC vs. TT: OR = 1.26, 95% CI = 1.12-1.43).
|
28630657 |
2017 |
|
Malignant neoplasm of prostate
|
|
0.030 |
GeneticVariation
|
BEFREE |
Recently, we showed that homozygous carriers for the T442C variant of the ARLTS1 gene (ADP-ribosylation factor-like tumour suppressor protein 1 or ARL11, located at 13q14) are associated with an increased risk for both unselected and familial PCa.
|
23940804 |
2013 |
|
Prostate carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Recently, we showed that homozygous carriers for the T442C variant of the ARLTS1 gene (ADP-ribosylation factor-like tumour suppressor protein 1 or ARL11, located at 13q14) are associated with an increased risk for both unselected and familial PCa.
|
23940804 |
2013 |
|
Malignant neoplasm of prostate
|
|
0.030 |
GeneticVariation
|
BEFREE |
Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.
|
22028916 |
2011 |
|
Prostate carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.
|
22028916 |
2011 |
|
Malignant Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
ARLTS1 variants, especially Cys148Arg (T442C), increase susceptibility to different cancers, including PCa.
|
22028916 |
2011 |
|
Prostate carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Our results suggest that Trp149Stop is not a predisposition allele in breast, prostate, or colorectal cancer in the Finnish population, and, while the Gly65Val variant may increase familial prostate cancer risk and the Cys148Arg change may affect both breast and prostate cancer risk, the evidence is not strong in these data.
|
18337727 |
2008 |
|
Malignant neoplasm of prostate
|
|
0.030 |
GeneticVariation
|
BEFREE |
Our results suggest that Trp149Stop is not a predisposition allele in breast, prostate, or colorectal cancer in the Finnish population, and, while the Gly65Val variant may increase familial prostate cancer risk and the Cys148Arg change may affect both breast and prostate cancer risk, the evidence is not strong in these data.
|
18337727 |
2008 |
|
Malignant Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
Whereas P131L and W149X did not seem to affect CRC risk, C148R did show, for the first time in CRC, statistically significant differences between cases and controls [odds ratio (OR) = 1.45, 95% confidence interval (95% CI) = 1.13-1.86, P = 0.003], sporadic cases and controls (OR = 1.59, 95% CI = 1.13-2.23, P = 0.007) and familial cases and controls (OR = 1.55, 95% CI = 1.10-2.19, P = 0.01) in agreement with a hypothetical moderate increase of the cancer risk linked to the C148R ARLTS1 variant, both in sporadic and familial CRC cases.
|
17449901 |
2007 |
|
Breast Cancer, Familial
|
|
0.030 |
GeneticVariation
|
BEFREE |
We studied the impact of the ARLTS1 Pro131Leu and Cys148Arg variants on high-risk familial and familial BC risk, investigating 482 familial BC cases (including 305 high-risk cases) and 530 control individuals.
|
16353159 |
2006 |
|
Breast Cancer, Familial
|
|
0.030 |
GeneticVariation
|
BEFREE |
Both Cys148Arg and Trp149Stop were associated with an increased risk of familial or high-risk familial breast cancer, respectively.
|
16646072 |
2006 |
|
Breast Cancer, Familial
|
|
0.030 |
GeneticVariation
|
BEFREE |
The Cys148Arg and Trp149Stop variants in the tumour suppressor gene ARLTS1 predispose to familial breast cancer, suggesting that these variants might also contribute to colorectal carcinogenesis.
|
16488076 |
2006 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
The stratification indicated that the Cys148Arg variant is significantly associated with sporadic cancer (CC vs. TT: OR = 1.36, 95% CI = 1.18-1.55) and familial cancer (CC vs. TT: OR = 1.26, 95% CI = 1.12-1.43).
|
28630657 |
2017 |
|
Prostate cancer, familial
|
|
0.020 |
GeneticVariation
|
BEFREE |
This study provides strong confirmation of the important role of ARLTS1 Cys148Arg variant as a contributor in PCa predisposition and a potential marker for aggressive disease outcome.
|
22028916 |
2011 |
|
Prostate cancer, familial
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our results suggest that Trp149Stop is not a predisposition allele in breast, prostate, or colorectal cancer in the Finnish population, and, while the Gly65Val variant may increase familial prostate cancer risk and the Cys148Arg change may affect both breast and prostate cancer risk, the evidence is not strong in these data.
|
18337727 |
2008 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our results suggest that Trp149Stop is not a predisposition allele in breast, prostate, or colorectal cancer in the Finnish population, and, while the Gly65Val variant may increase familial prostate cancer risk and the Cys148Arg change may affect both breast and prostate cancer risk, the evidence is not strong in these data.
|
18337727 |
2008 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.020 |
GeneticVariation
|
BEFREE |
Association of the ARLTS1 Cys148Arg variant with sporadic and familial colorectal cancer.
|
17449901 |
2007 |
|
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
Whereas P131L and W149X did not seem to affect CRC risk, C148R did show, for the first time in CRC, statistically significant differences between cases and controls [odds ratio (OR) = 1.45, 95% confidence interval (95% CI) = 1.13-1.86, P = 0.003], sporadic cases and controls (OR = 1.59, 95% CI = 1.13-2.23, P = 0.007) and familial cases and controls (OR = 1.55, 95% CI = 1.10-2.19, P = 0.01) in agreement with a hypothetical moderate increase of the cancer risk linked to the C148R ARLTS1 variant, both in sporadic and familial CRC cases.
|
17449901 |
2007 |
|
Familial (FPAH)
|
|
0.020 |
GeneticVariation
|
BEFREE |
Whereas P131L and W149X did not seem to affect CRC risk, C148R did show, for the first time in CRC, statistically significant differences between cases and controls [odds ratio (OR) = 1.45, 95% confidence interval (95% CI) = 1.13-1.86, P = 0.003], sporadic cases and controls (OR = 1.59, 95% CI = 1.13-2.23, P = 0.007) and familial cases and controls (OR = 1.55, 95% CI = 1.10-2.19, P = 0.01) in agreement with a hypothetical moderate increase of the cancer risk linked to the C148R ARLTS1 variant, both in sporadic and familial CRC cases.
|
17449901 |
2007 |
|
Familial (FPAH)
|
|
0.020 |
GeneticVariation
|
BEFREE |
Both Cys148Arg and Trp149Stop were associated with an increased risk of familial or high-risk familial breast cancer, respectively.
|
16646072 |
2006 |
|
Hereditary Malignant Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
The stratification indicated that the Cys148Arg variant is significantly associated with sporadic cancer (CC vs. TT: OR = 1.36, 95% CI = 1.18-1.55) and familial cancer (CC vs. TT: OR = 1.26, 95% CI = 1.12-1.43).
|
28630657 |
2017 |